Sclerosing Activity and Thrombogenic Potential of a COVID-19 mRNA Vaccine Metabolite: New Evidence of Its Contribution to the Pathogenesis of Adverse Cardiovascular Reactions, Including Fatal Outcomes

A previous study published in this journal identified a fundamental inconsistency in the pharmacokinetic dossiers for Pfizer/BioNTech’s Comirnaty mRNA vaccine: the substitution, in the documentation, of the actual ALC-0315 metabolite, 2-hexyldecanoic acid, with the “phantom”, untraceable isomer 6-hexyldecanoic acid. Beyond circumventing the Aquatic Chronic 1 (H410) toxicological classification and the inhibition of mitochondrial β-oxidation attributable to steric hindrance from branching at C2, chemical, historical and pharmacological evidence now points to substantially more serious concerns. Authoritative chemical reference works explicitly classify 2-hexyldecanoic acid and its sodium salt as “sclerosing agents”. This review examines the membrane-disruptive and endothelium-damaging activity of the anionic form of 2-hexyldecanoic acid, a detergent surfactant, and analyses its direct relationship with the induction of tissue necrosis, chemical phlebitis and the ensuing thrombogenic cascade. These mechanisms provide an incontrovertible biochemical and aetiopathogenic rationale for the occurrence of severe cardiovascular adverse events - including thrombosis, myocarditis and pericarditis - observed after vaccination on a large scale, constituting an unprecedented violation of the Precautionary Principle.